Freeline Therapeutics Holdings plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRLN research report →
Companywww.freeline.life
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial.
- CEO
- Michael J. Parini
- IPO
- 2020
- Employees
- 152
- HQ
- Stevenage, GB
Price Chart
Valuation
- Market Cap
- $28.28M
- P/E
- -0.29
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -102.94%
- ROIC
- -168.75%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-88,972,000 · 36.63%
- EPS
- $-22.52 · 61.82%
- Op Income
- $-98,447,000
- FCF YoY
- 23.78%
Performance & Tape
- 52W High
- $8.74
- 52W Low
- $2.11
- 50D MA
- $6.40
- 200D MA
- $4.57
- Beta
- 0.66
- Avg Volume
- 28.14K
Get TickerSpark's AI analysis on FRLN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FRLN Coverage
We haven't published any research on FRLN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FRLN Report →